Product Sales & Royalties was Eton Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $76.66M of $79.95M (96%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Product Sales & Royalties | — | $11.25M | $26.14M | $38.51M | — | $76.66M | |||
| License | $5.00M | $10.00M | $5.50M | $500.00K | — | $3.29M | |||
| Increlex | — | — | — | — | $1.79M | — | |||
| Licensing Revenue | — | — | — | — | — | — | |||
| Product | — | — | — | — | — | — | |||
| Total | $5.00M | $21.25M | $31.64M | $39.01M | $1.79M | $79.95M |
Eton Pharmaceuticals brought in $79.95M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Eton Pharmaceuticals regrouped these lines after fiscal 2025, so the total does not compare directly with that year's $1.79M. Product Sales & Royalties was the largest at $76.66M (95.9%), ahead of License at $3.29M (4.1%).
Eton Pharmaceuticals stopped reporting Increlex as a separate line after fiscal 2025, when it brought in $1.79M.
Scenario Three was Eton Pharmaceuticals’s largest revenue line in fiscal 2019, bringing in $50.00M of $80.00M (63%).
| Statement Scenario | FY 2019 |
|---|---|
| Scenario Three | $50.00M |
| Scenario Two | $20.00M |
| Scenario One | $10.00M |
| Total | $80.00M |
Eton Pharmaceuticals brought in $80.00M from its three revenue lines in fiscal 2019, the year ended June 12, 2019. Scenario Three was the largest at $50.00M (62.5%), ahead of Scenario Two at $20.00M (25.0%) and Scenario One at $10.00M (12.5%).
Eton Pharmaceuticals (ETON) reports its revenue by product and service and by statement scenario. In fiscal 2025, Product Sales & Royalties was its largest product and service line, bringing in $76.66M (95.9% of the total), followed by License at $3.29M (4.1%).
Product Sales & Royalties was Eton Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $76.66M, or 95.9% of the $79.95M total across its two product and service lines.
Scenario Three was Eton Pharmaceuticals' largest revenue line in fiscal 2019, bringing in $50.00M, or 62.5% of the $80.00M total across its three revenue lines.
Every figure comes from Eton Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Eton Pharmaceuticals gives it, and years follow its fiscal calendar.
Eton Pharmaceuticals' revenue by product and service goes back to fiscal 2019, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.